JHMD - ETF AI Analysis
Top Page
John Hancock Multifactor Developed International ETF (JHMD)
Rating:65Neutral
Price Target:―
Positive Factors
Improving Recent Performance
The ETF has shown steady gains over the past three months and month-to-date, indicating positive recent momentum.
Broad Country Diversification
Holdings spread across many developed markets like Japan, the UK, Germany, and others help reduce the impact of weakness in any single country.
Supportive Top Holdings
Several of the largest positions, including ASML, Novartis, HSBC, Roche, E.ON, and Engie, have delivered strong or steady year-to-date results that support the fund’s overall performance.
Negative Factors
Moderate Expense Ratio
The fund’s expense ratio is not especially low for an ETF, which slightly reduces the net return investors keep over time.
Mixed Performance Among Top Holdings
Some key positions such as Vinci, Shell, and BASF have shown weaker year-to-date performance, which can drag on the fund’s returns.
Heavy Tilt Toward Financials and Industrials
Large weights in financial and industrial stocks mean the ETF could be more sensitive if these sectors face a downturn.
JHMD vs. SPDR S&P 500 ETF (SPY)
AUM1.15B
RegionDeveloped Markets
Expense Ratio0.39%
Beta0.69
IssuerJohn Hancock
Inception DateDec 15, 2016
Dividend Yield3.25%
Asset ClassEquity
Index TrackedJohn Hancock Dimensional Developed International Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume169,256
30 Day Avg. Volume156,268
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
47.64Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering570
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
JHMD Summary
John Hancock Multifactor Developed International ETF (JHMD) tracks the John Hancock Dimensional Developed International Index, giving you broad exposure to stocks in developed countries outside the U.S., such as Japan, the UK, and Germany. It owns many types of companies across sectors, including well-known names like ASML Holding and Novartis. Investors might consider JHMD to diversify beyond the U.S. market and spread risk across many international industries and company sizes. A key risk is that international stocks can be volatile and are affected by foreign economies, currencies, and political events, so the value can go up and down.
How much will it cost me?The John Hancock Multifactor Developed International ETF (JHMD) has an expense ratio of 0.39%, which means you’ll pay $3.90 per year for every $1,000 invested. This cost is slightly higher than average for passively managed ETFs because it uses a multifactor strategy to optimize risk and reward across developed international markets.
What would affect this ETF?Positive drivers for JHMD include potential economic growth in developed international markets outside North America, which could boost the performance of its top holdings like Vinci SA and Novartis AG. However, negative factors such as rising interest rates or economic slowdowns in Europe could impact sectors like Financials and Industrials, which make up a significant portion of the ETF's exposure.
JHMD Top 10 Holdings
JHMD is leaning on a mix of European industrials, health care, and financials to do the heavy lifting. ASML has been a key engine, rising on the back of strong chip demand, while Novartis and Roche add steady, upward momentum from the pharma side. Utilities like Engie and E.ON have quietly supported returns, acting like ballast in choppy markets. On the flip side, BBVA has been lagging and occasionally drags on the fund’s financial sleeve. Overall, it’s a developed-markets, ex-North America story with a distinctly European flavor.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Vinci SA | 1.79% | $20.70M | €69.18B | 4.81% | 76 Outperform | |
| ASML Holding NV | 1.70% | $19.67M | €430.96B | 70.82% | 76 Outperform | |
| Engie SA | 1.10% | $12.71M | €67.03B | 50.84% | 64 Neutral | |
| BASF SE | 1.01% | $11.72M | €41.06B | -7.28% | 61 Neutral | |
| Banco Bilbao Vizcaya Argentaria | 0.97% | $11.24M | €102.08B | 39.06% | 76 Outperform | |
| HSBC Holdings | 0.92% | $10.64M | £196.52B | 29.79% | 80 Outperform | |
| Novartis AG | 0.88% | $10.12M | CHF220.01B | 16.50% | 80 Outperform | |
| BP p.l.c. | 0.86% | $10.00M | £86.43B | 24.96% | 71 Outperform | |
| Bayer | 0.84% | $9.68M | €37.71B | 60.89% | 54 Neutral | |
| Shell (UK) | 0.83% | $9.58M | £193.19B | 25.92% | 73 Outperform |
JHMD Technical Analysis
Negative
―
Price Trends
43.72
Negative
42.11
Negative
40.29
Positive
Market Momentum
-0.69
Positive
29.62
Positive
19.28
Positive
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For JHMD, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 43.52, equal to the 50-day MA of 43.72, and equal to the 200-day MA of 40.29, indicating a neutral trend. The MACD of -0.69 indicates Positive momentum. The RSI at 29.62 is Positive, neither overbought nor oversold. The STOCH value of 19.28 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JHMD.
JHMD Peer Comparison
Comparison Results
Performance Comparison
JHMD
John Hancock Multifactor Developed International ETF
40.78
6.28
18.20%
JIRE
JPMorgan International Research Enhanced Equity ETF
―
―
―
FENI
Fidelity Enhanced International ETF
―
―
―
BBIN
JPMorgan BetaBuilders International Equity ETF
―
―
―
EFAV
iShares MSCI EAFE Min Vol Factor ETF
―
―
―
IHDG
WisdomTree International Hedged Quality Dividend Growth Fund
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents